Formulation and Characterization of Metformin Buccal films for T2DM

The drug delivery platform known as buccal films provides systemic medication access to precise target locations through the elimination of hepatic first-pass effect. The drug delivery format provides added convenience for patients during medication use. Metformin hydrochloride (Met) shows limited bioavailability as an antidiabetic drug because it has high solubility yet poor permeability. The present study aimed to develop metformin buccal films which would leverage the drug's therapeutic capabilities. The metformin buccal films were developed through solvent-casting methodology which incorporatedpolyvinyl alcohol (PVA) as polymer base material. Developing the formulation involved adding PEG 400 as plasticizer and sodium starch glycolate as disintegrant. Different ratios of PVA and SSG resulted in six distinct formulations (F1 to F6). Mannitol served as both a sweetening agent and a dissolution enhancer for the formulation. Buccal film evaluations included assessments of weight variation together with thickness measurements and folding endurance investigations as well as surface pH determinations and content uniformity testing and thermal stability measurements and tensile strength and percentage ofelongation assessments. In vitro dissolution testing revealed that the disintegration time for all formulations remained beneath 60 minutes because of the disintegrant's influence. The drug release from Formulation F4 reached 99 % within a period of 60 minutes.